


Study improves prediction of therapy response in patients with metastatic renal cell carcinoma


June 22 2023, by Inka V  th

A OS probability in patients with baseline mGPS of 0




No. at risk	428	427	418	407	389	288	161	88	20
All patients	428	427	418	407	389	288	161	88	20
mGPS 0	353	353	348	340	325	247	144	81	18
mGPS 1	68	67	65	62	59	37	17	7	2
mGPS 2	7	7	5	5	5	4	0	0	0

B OS probability in patients with baseline mGPS of 1




No. at risk	222	221	207	184	165	115	65	24	6
All patients	222	221	207	184	165	115	65	24	6
mGPS 0	83	83	83	79	75	52	29	12	1
mGPS 1	113	112	104	90	78	56	33	12	5
mGPS 2	26	26	20	15	12	7	3	0	0

C PFS probability in patients with baseline mGPS of 0



No. at risk	428	382	338	272	225	155	62	19	2
All patients	428	382	338	272	225	155	62	19	2
mGPS 0	353	324	288	236	200	142	57	17	2
mGPS 1	68	54	47	34	23	13	5	2	0
mGPS 2	7	4	3	2	2	0	0	0	0

D PFS probability in patients with baseline mGPS of 1



No. at risk	222	178	137	103	84	54	21	6	0
All patients	222	178	137	103	84	54	21	6	0
mGPS 0	83	77	69	57	46	28	13	3	0
mGPS 1	113	83	61	42	35	24	8	3	0
mGPS 2	26	18	7	4	3	2	0	0	0

Outcome Predictions of the On-Treatment Modified Glasgow Prognostic Score (mGPS) in the IMmotion151 Discovery Cohort On-treatment mGPS in the subgroups with baseline mGPS low (mGPS 0) and intermediate (mGPS 1) risk

provides prognostic information regarding both overall survival (OS) and progression-free survival (PFS). In the high-risk subgroup (mGPS 2), the on-treatment mGPS is depicted in eFigure 2 in Supplement 1. For reference, in the present Figure, the Kaplan-Meier curve of the entire baseline mGPS subgroup (all patients) is shown in each panel. Credit: *JAMA Oncology* (2023).

doi:10.1001/jamaoncol.2023.1822

Dr. Niklas Klümper, resident at the Department of Urology of the University Hospital Bonn (UKB) and working group leader at the Institute for Experimental Oncology (IEO), and Dr. Jonas Saal, resident at the Medical Clinic III for Hematology and Oncology of the UKB, demonstrated a significant improvement in predicting the response to therapy in metastatic renal cell carcinoma by incorporating the level of inflammation, which was assessed using two straightforward blood parameters, alongside the conventional imaging-based approach.

Renal cell carcinoma is the most common form of kidney cancer. To treat metastatic renal cancer, combinations of immunotherapies are used as the first line of treatment. These are designed to activate the patient's immune system to recognize and fight malignant cancer cells. These highly effective first-line therapies currently achieve [disease control](#) in over 80% of patients with metastatic renal cell carcinoma.

Reliable prediction of response to treatment is critical for optimal patient management. However, in daily clinical practice, only imaging (usually by computed tomography (CT)) with vague estimation of tumor volume is used to evaluate treatment response. However, looking at tumor volume alone does not adequately predict who will benefit from immunotherapy in the long term. Complementary markers to predict further disease progression are therefore essential to further optimize and guide therapy.

Improvement of the therapy response in the blood

The research group led by Dr. Klümper has now been able to show that the investigation of two inexpensive and widely available inflammatory markers in the blood (C-reactive protein (CRP) and albumin) significantly improves the prediction of therapy response in patients with metastatic renal cell carcinoma, especially in the large group of patients with disease control in the first follow-up (>80%). The authors concluded that both radiologic imaging and complementary analysis of inflammation levels should be used for monitoring in patients with metastatic renal cell carcinoma in the future.

"Our novel approach for enhanced therapy monitoring and prediction of treatment response is based on the combination of imaging and the assessment of inflammation level through the collection of two simple blood parameters: CRP and albumin integrated into the well-known modified Glasgow Prognosis Score (mGPS). Our study's findings are derived from patient cohorts participating in two separate randomized trials focused on metastatic renal cell [carcinoma](#). These results strongly advocate for the immediate implementation of the mGPS as a prognostic tool for predicting outcomes in individuals diagnosed with metastatic [renal cell carcinoma](#)," said Dr. Niklas Klümper.

The mGPS is determined by assigning one point for an elevated serum CRP concentration (> 10 mg/L) and, only in patients with elevated CRP, a second point for decreased serum albumin (

"Both blood parameters are widely available and inexpensive to determine, and thus can be immediately integrated into [clinical practice](#) worldwide to improve therapy monitoring of cancer patients. Improved prediction of treatment failure could better identify patients who could benefit from a change or intensification of therapy. This concept needs to be explored in future studies," said Dr. Jonas Saal.

The study was published in *JAMA Oncology*.

More information: Jonas Saal et al, Integrating On-Treatment Modified Glasgow Prognostic Score (mGPS) and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma, *JAMA Oncology* (2023). [DOI: 10.1001/jamaoncol.2023.1822](https://doi.org/10.1001/jamaoncol.2023.1822).
[jamanetwork.com/journals/jamao ... /fullarticle/2806576](https://jamanetwork.com/journals/jamao.../fullarticle/2806576)

Provided by Universitätsklinikum Bonn

Citation: Study improves prediction of therapy response in patients with metastatic renal cell carcinoma (2023, June 22) retrieved 11 May 2024 from
<https://medicalxpress.com/news/2023-06-therapy-response-patients-metastatic-renal.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--